Advanced Gastrointestinal Stromal Tumors (GISTs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Gastrointestinal stromal tumors (GISTs) represent 0.1–0.3% of gastrointestinal malignant neoplasms and are primarily located within the mesenchymal tissue of the gastrointestinal tract. These tumors can manifest at any age, with a median patient age of 60–65 years. Clinically, GISTs often present with symptoms such as gastrointestinal bleeding, anemia, and abdominal pain. The stomach is the most common site of occurrence, accounting for approximately 50–60% of cases, followed by the small intestine (20–30%) and, less frequently, the colon and rectum (5%) and the esophagus (<1%). Metastatic disease is identified in approximately 15% of patients at diagnosis. Before the advent of targeted therapies, the management of GISTs was challenging due to their poor response to conventional chemotherapy and radiation, making surgical resection the primary therapeutic option. However, many patients who initially undergo surgery for GISTs eventually experience disease recurrence. Historically, the prognosis for patients with advanced GISTs has been poor, with limited effective treatment options available. Significant progress was made with the approval of ripretinib by the Food and Drug Administration (FDA) on May 15, 2020. This drug is indicated for adult patients with advanced GISTs who have previously been treated with three or more kinase inhibitors, including imatinib.

Thelansis’s “Advanced Gastrointestinal Stromal Tumors (GISTs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced Gastrointestinal Stromal Tumors (GISTs) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Advanced Gastrointestinal Stromal Tumors (GISTs) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Advanced Gastrointestinal Stromal Tumors (GISTs) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Advanced Gastrointestinal Stromal Tumors (GISTs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033